Abbott Laboratories (ABT)
|Net Income (ttm)||4.50B|
|Trading Day||April 16|
|Day's Range||122.95 - 124.61|
|52-Week Range||84.89 - 128.07|
More than 300 publicly traded companies are expected to report March quarter earnings next week as earnings season revs up.
Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.
Abbott stock is scheduled to report its Q1 2021 results on Tuesday, April 20. We expect Abbott to report revenues in-line and earnings above the consensus estimates, driven by continued demand for Covid...
Abbott (ABT) closed at $123.01 in the latest trading session, marking a +1.63% move from the prior day.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Two additional regulatory approvals in Europe are expected to have widened Abbott's (ABT) global Panbio customer base through Q1, contributing to the top line.
Per Abbott's (ABT) TRILUMINATE CE Mark study, the latest version shows sustained symptomatic improvement, reduction in the severity of TR and improvement in functional status.
World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Oly...
ABBOTT PARK, Ill., April 12, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it is teaming up with Eliud Kipchoge, who is considered the world's fastest marathon runner, and the NN Running Team ...
Two elements will send revenue soaring in the coming months.
Abbott Laboratories (NYSE: ABT) won European approval for the latest generation of its TriClip system, a transcatheter-based repair device designed to stem leaks in the heart's tricuspid valve. The tric...
Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Va...
ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its...
The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.
Abbott Laboratories' (NYSE: ABT) XIENCE stent has received CE Mark in Europe for a shorter duration of dual antiplatelet therapy (DAPT) – as short as 28 days for patients with high bleeding risk (HBR). ...
Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding R...
ABBOTT PARK, Ill., April 6, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short a...
According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.
Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.
Abbott Labs looks attractive at current levels of $120, despite the stock rising 2x from levels of $62 it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This...
Abbott (ABT) closed the most recent trading day at $118.94, moving -0.75% from the previous trading session.
Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counte...
ABBOTT PARK, Ill., March 31, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for over-the-counter, non-p...
For a little less volatility and a little more dependability in 2021, check out these companies.
Is (ABT) Outperforming Other Medical Stocks This Year?
ABBOTT PARK, Ill., March 29, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2021 financial results on Tuesday, April 20, 2021, before the market opens.
These stocks should still be winners long after the pandemic is over.
Grab these three top stocks - ABT, HOLX and BIO - that continue to show tremendous promise and stand to benefit from the historic stimulus package.
Within Medical Device, Abbott (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Abbott (ABT) closed at $120.49 in the latest trading session, marking a -0.81% move from the prior day.
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
The medical device company's stock generated 49% returns over just the past year.
The key words are "growth" and "recovery."
In the latest trading session, Abbott (ABT) closed at $117.62, marking a -0.51% move from the previous day.
Is (ABT) Outperforming Other Medical Stocks This Year?
Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.
Abbott (ABT) closed the most recent trading day at $117.52, moving +1.42% from the previous trading session.
Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Fu...
ABBOTT PARK, Ill., March 11, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific and public health partn...
Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.
Abbott's (ABT) Alinity m SARS-CoV-2 test set to detect COVID-19 in individuals who do not have symptoms.
In the latest trading session, Abbott (ABT) closed at $117.25, marking a +1.07% move from the previous day.
The FDA has granted Emergency Use Authorization (EUA) for Abbott Laboratories' (NYSE: ABT) Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B, and res...
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
We believe that there are several stocks in the healthcare sector that are better than Abbott Labs. Abbott's current market cap-to-operating income ratio of 41x compares with 12x for Emergent Biosolutio...
Abbott's (ABT) FreeStyle Libre is the only glucose sensing technology available in Canada to remotely monitor glucose status in an expectant mother to reduce exposure to COVID-19.
The pandemic won't always be a pandemic, but the virus is going to with us as an endemic part of life. That's the message from a new piece on Reuters.
Abbott Laboratories (NYSE: ABT) has announced a potential research breakthrough that could lead to advancements and potential vaccines for the treatment of HIV. What Happened: Abbott's researchers have ...
Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure
ABBOTT PARK, Ill., March 2, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) who t...
Abbott (ABT) possesses solid growth attributes, which could help it handily outperform the market.
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidi... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, ABT's revenue was $34.61 billion, an increase of 8.48% compared to the previous year's $31.90 billion. Earnings were $4.50 billion, an increase of 21.91%.
According to 21 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 134.95, which is an increase of 8.52% from the latest price.